详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]School of Basic Medical Sciences, WenzhouMedical University, Wenzhou, Zhejiang,325035, People’s Republic of China [2]School ofStomatology, Wenzhou Medical University,Wenzhou, Zhejiang, 325035, People’s Republicof China [3]Department of Surgery, ChengduShuangliu District Maternal and Child HealthHospital, ChengDu, Sichuan, 610200, People’sRepublic of China [4]Department ofStomatology, Haiyuan College, Kunming,Yunnan, 650106, People’s Republic of China [5]Department of General Medicine, FirstAffiliated Hospital, Wenzhou MedicalUniversity, Wenzhou, 325000, People’sRepublic of China

出处：

DOI：

ISSN：

关键词： magnetic thermosensitive cationic liposome oxaliplatin antisense lncRNA of MDC1 targeted therapy cervical cancer

摘要：

This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer. Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined. The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery. The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer. © 2021 Ye et al.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 2 区药学 3 区纳米科技

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区药学 3 区纳米科技

第一作者：

第一作者机构： [1]School of Basic Medical Sciences, WenzhouMedical University, Wenzhou, Zhejiang,325035, People’s Republic of China [*1]School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People’s Republic of China

共同第一作者：

通讯作者：

通讯机构： [1]School of Basic Medical Sciences, WenzhouMedical University, Wenzhou, Zhejiang,325035, People’s Republic of China [5]Department of General Medicine, FirstAffiliated Hospital, Wenzhou MedicalUniversity, Wenzhou, 325000, People’sRepublic of China [*1]School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People’s Republic of China [*2]Department of General Medicine, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Advances in systemic treatment for recurrent metastatic cervical cancer [2]Advances in systemic treatment for recurrent metastatic cervical cancer [3]Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs [4]YB-1 as an Oncoprotein: Functions, Regulation, Post-Translational Modifications, and Targeted Therapy [5]CCT3 as a Diagnostic and Prognostic Biomarker in Cervical Cancer [6]晚期结直肠癌精准分子靶向治疗研究进展 [7]急性髓系白血病靶向治疗的研究进展 [8]The role of NFATc1/c-myc/PKM2/IL-10 axis in activating cervical cancer tumor-associated M2 macrophage polarization to promote cervical cancer progression. [9]Nujiangexanthone A Inhibits Cervical Cancer Cell Proliferation by Promoting Mitophagy [10]Roles of RNF126 and BCA2 E3 ubiquitin ligases in DNA damage repair signaling and targeted cancer therapy